GEN Exclusives

More »

GEN News Highlights

More »
Jul 15, 2009

BioWa Grants Merck KGaA Access to Technology that Enhances Antibody-Dependent Cellular Cytotoxicity

  • Merck KGaA licensed access to BioWa's Potelligent® Technology for the research, development, and commercialization of its antibody therapies. Under this nonexclusive agreement, BioWa received up-front fees and may earn development milestone payments and royalties.

    Potelligent is designed to improve potency and efficacy of antibody therapeutics by enhancing antibody-dependent cellular cytotoxicity. It involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?